#BEGIN_DRUGCARD DB02196

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C17H27N3O17P2

# Chemical_IUPAC_Name:
[({[(2R,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy]({[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})phosphinic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Uridine-Diphosphate-N-Acetylgalactosamine

# HET_ID:
UD2

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C17H27N3O17P2/c1-6(22)18-10-13(26)11(24)7(4-21)35-16(10)36-39(31,32)37-38(29,30)33-5-8-12(25)14(27)15(34-8)20-3-2-9(23)19-17(20)28/h2-3,7-8,10-16,21,24-27H,4-5H2,1H3,(H,18,22)(H,29,30)(H,31,32)(H,19,23,28)/t7-,8-,10-,11+,12-,13-,14-,15-,16-/m1/s1

# InChI_Key:
InChIKey=LFTYTUAZOPRMMI-NESSUJCYSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
2196

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
607.3537

# Molecular_Weight_Mono:
607.081569477

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1I3N

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-1.4

# Predicted_LogS:
-1.7

# Predicted_Water_Solubility:
1.14e+01 g/l

# Primary_Accession_No:
DB02196

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
23700

# PubChem_Substance_ID:
46508676

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT03169

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[P@](O)(=O)O[P@](O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:53 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
EXTL2

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7139

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Exostosin-like 2

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q9UBQ6

# Drug_Target_1_SwissProt_Name:
EXTL2_HUMAN

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

# Drug_Target_2_Cellular_Location:
Cytoplasm. Note=In spermatozoa, localized to the principal piece of the tail, the neck region of the

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
UAP1

# Drug_Target_2_GenBank_ID_Gene:
S73498

# Drug_Target_2_GenBank_ID_Protein:
7717462

# Drug_Target_2_GeneCard_ID:
UAP1

# Drug_Target_2_Gene_Name:
UAP1

# Drug_Target_2_Gene_Sequence:
>1518 bp
ATGAACATTAATGACCTCAAACTCACGTTGTCCAAAGCTGGGCAAGAGCACCTACTACGT
TTCTGGAATGAGCTTGAAGAAGCCCAACAGGTAGAACTTTATGCAGAGCTCCAGGCCATG
AACTTTGAGGAGCTGAACTTCTTTTTCCAAAAGGCCATTGAAGGTTTTAACCAGTCTTCT
CACCAAAAGAATGTGGATGCACGAATGGAACCTGTGCCTCGAGAGGTATTAGGCAGTGCT
ACAAGGGATCAAGATCAGCTCCAGGCCTGGGAAAGTGAAGGACTTTTCCAGATTTCTCAG
AATAAAGTAGCAGTTCTTCTTCTAGCTGGTGGGCAGGGGACAAGACTCGGCGTTGCATAT
CCTAAGGGGATGTATGATGTTGGTTTGCCATCCCGTAAGACACTTTTTCAGATTCAAGCA
GAGCGTATCCTGAAGCTACAGCAGGTTGCTGAAAAATATTATGGCAACAAATGCATTATT
CCATGGTATATAATGACCAGTGGCAGAACAATGGAATCTACAAAGGAGTTCTTCACCAAG
CACAAGTACTTTGGTTTAAAAAAAGAGAATGTAATCTTTTTTCAGCAAGGAATGCTCCCC
GCCATGAGTTTTGATGGGAAAATTATTTTGGAAGAGAAGAACAAAGTTTCTATGGCTCCA
GATGGGAATGGTGGTCTTTATCGGGCACTTGCAGCCCAGAATATTGTGGAGGATATGGAG
CAAAGAGGCATTTGGAGCATTCATGTCTATTGTGTTGACAACATATTAGTAAAAGTGGCA
GACCCACGGTTCATTGGATTTTGCATTCAGAAAGGAGCAGACTGTGGAGCAAAGGTGGTA
GAGAAAACGAACCCTACAGAACCAGTTGGAGTGGTTTGCCGAGTGGATGGAGTTTACCAG
GTGGTAGAATATAGTGAGATTTCCCTGGCAACAGCTCAAAAACGAAGCTCAGACGGACGA
CTGCTGTTCAATGCGGGGAACATTGCCAACCATTTCTTCACTGTACCATTTCTGAGAGAT
GTTGTCAATGTTTATGAACCTCAGTTGCAGCACCATGTGGCTCAAAAGAAGATTCCTTAT
GTGGATACCCAAGGACAGTTAATTAAGCCAGACAAACCCAATGGAATAAAGATGGAAAAA
TTTGTCTTTGACATCTTCCAGTTTGCAAAGAAGTTTGTGGTATATGAAGTATTGCGAGAA
GATGAGTTTTCCCCACTAAAGAATGCTGATAGTCAGAATGGGAAAGACAACCCTACTACT
GCAAGGCATGCTTTGATGTCCCTTCATCATTGCTGGGTCCTCAATGCAGGGGGCCATTTC
ATAGATGAAAATAGCTCTCGCCTTCCAGCAATTCCCCGCTTGAAGGATGCCAATGATGTA
CCAATCCAATGTGAAATCTCTCCTCTTATCTCCTATGCTGGAGAAGGATTAGAAAGTTAT
GTGGCAGATAAAGAATTCCATGCACCTCTAATCATCGATGAGAATGGAGTTCATGAGCTG
GTGAAAAATGGTATTTGA

# Drug_Target_2_General_Function:
Involved in nucleotidyltransferase activity

# Drug_Target_2_General_References:
8025165	Diekman AB, Goldberg E: Characterization of a human antigen with sera from infertile patients. Biol Reprod. 1994 May;50(5):1087-93.
9603950	Mio T, Yabe T, Arisawa M, Yamada-Okabe H: The eukaryotic UDP-N-acetylglucosamine pyrophosphorylases. Gene cloning, protein expression, and catalytic mechanism. J Biol Chem. 1998 Jun 5;273(23):14392-7.
9765219	Wang-Gillam A, Pastuszak I, Elbein AD: A 17-amino acid insert changes UDP-N-acetylhexosamine pyrophosphorylase specificity from UDP-GalNAc to UDP-GlcNAc. J Biol Chem. 1998 Oct 16;273(42):27055-7.

# Drug_Target_2_HGNC_ID:
HGNC:12457

# Drug_Target_2_HPRD_ID:
04178

# Drug_Target_2_ID:
2612

# Drug_Target_2_Locus:
1q23.3

# Drug_Target_2_Molecular_Weight:
58770

# Drug_Target_2_Name:
UDP-N-acetylhexosamine pyrophosphorylase

# Drug_Target_2_Number_of_Residues:
522

# Drug_Target_2_PDB_ID:
1JVG

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF01704	UDPGP

# Drug_Target_2_Protein_Sequence:
>UDP-N-acetylhexosamine pyrophosphorylase
MNINDLKLTLSKAGQEHLLRFWNELEEAQQVELYAELQAMNFEELNFFFQKAIEGFNQSS
HQKNVDARMEPVPREVLGSATRDQDQLQAWESEGLFQISQNKVAVLLLAGGQGTRLGVAY
PKGMYDVGLPSRKTLFQIQAERILKLQQVAEKYYGNKCIIPWYIMTSGRTMESTKEFFTK
HKYFGLKKENVIFFQQGMLPAMSFDGKIILEEKNKVSMAPDGNGGLYRALAAQNIVEDME
QRGIWSIHVYCVDNILVKVADPRFIGFCIQKGADCGAKVVEKTNPTEPVGVVCRVDGVYQ
VVEYSEISLATAQKRSSDGRLLFNAGNIANHFFTVPFLRDVVNVYEPQLQHHVAQKKIPY
VDTQGQLIKPDKPNGIKMEKFVFDIFQFAKKFVVYEVLREDEFSPLKNADSQNGKDNPTT
ARHALMSLHHCWVLNAGGHFIDENGSRLPAIPRSATNGKSETITADVNHNLKDANDVPIQ
CEISPLISYAGEGLESYVADKEFHAPLIIDENGVHELVKNGI

# Drug_Target_2_Reaction:
UTP + N-acetyl-alpha-D-glucosamine 1-phosphate = diphosphate + UDP-N-acetyl-D-glucosamine

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Converts UDP and GlcNAc-1-P into UDP-GlcNAc, and UDP and GalNAc-1-P into UDP-GalNAc. Isoform AGX1 has 2 to 3 times higher activity towards GalNAc-1-P, while isoform AGX2 has 8 times more activity towards GlcNAc-1-P

# Drug_Target_2_SwissProt_ID:
Q16222

# Drug_Target_2_SwissProt_Name:
UAP1_HUMAN

# Drug_Target_2_Synonyms:
AGX
AGX-1
Antigen X
EC 2.7.7.-
EC 2.7.7.23
Sperm- associated antigen 2
UDP-N-acetylglucosamine pyrophosphorylase

# Drug_Target_2_Theoretical_pI:
6.29

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
GALE

# Drug_Target_3_GenBank_ID_Gene:
L41668

# Drug_Target_3_GenBank_ID_Protein:
1119217

# Drug_Target_3_GeneCard_ID:
GALE

# Drug_Target_3_Gene_Name:
GALE

# Drug_Target_3_Gene_Sequence:
>1047 bp
ATGGCAGAGAAGGTGCTGGTAACAGGTGGGGCTGGCTACATTGGCAGCCACACGGTGCTG
GAGCTGCTGGAGGCTGGCTACTTGCCTGTGGTCATCGATAACTTCCATAATGCCTTCCGT
GGAGGGGGCTCCCTGCCTGAGAGCCTGCGGCGGGTCCAGGAGCTGACAGGCCGCTCTGTG
GAGTTTGAGGAGATGGACATTTTGGACCAGGGAGCCCTACAGCGTCTCTTCAAAAAGTAC
AGCTTTATGGCGGTCATCCACTTTGCGGGGCTCAAGGCCGTGGGCGAGTCGGTGCAGAAG
CCTCTGGATTATTACAGAGTTAACCTGACCGGGACCATCCAGCTTCTGGAGATCATGAAG
GCCCACGGGGTGAAGAACCTGGTGTTCAGCAGCTCAGCCACTGTGTACGGGAACCCCCAG
TACCTGCCCCTTGATGAGGCCCACCCCACGGGTGGTTGTACCAACCCTTACGGCAAGTCC
AAGTTCTTCATCGAGGAAATGATCCGGGACCTGTGCCAGGCAGACAAGACTTGGAACGTA
GTGCTGCTGCGCTATTTCAACCCCACAGGTGCCCATGCCTCTGGCTGCATTGGTGAGGAT
CCCCAGGGCATACCCAACAACCTCATGCCTTATGTCTCCCAGGTGGCGATCGGGCGACGG
GAGGCCCTGAATGTCTTTGGCAATGACTATGACACAGAGGATGGCACAGGTGTCCGGGAT
TACATCCATGTCGTGGATCTGGCCAAGGGCCACATTGCAGCCTTAAGGAAGCTGAAAGAA
CAGTGTGGCTGCCGGATCTACAACCTGGGCACGGGCACAGGCTATTCAGTGCTGCAGATG
GTCCAGGCTATGGAGAAGGCCTCTGGGAAGAAGATCCCGTACAAGGTGGTGGCACGGCGG
GAAGGTGATGTGGCAGCCTGTTACGCCAACCCCAGCCTGGCCCAAGAGGAGCTGGGGTGG
ACAGCAGCCTTAGGGCTGGACAGGATGTGTGAGGATCTCTGGCGCTGGCAGAAGCAGAAT
CCTTCAGGCTTTGGCACGCAAGCCTGA

# Drug_Target_3_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_3_General_References:
10801319	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Crystallographic evidence for Tyr 157 functioning as the active site base in human UDP-galactose 4-epimerase. Biochemistry. 2000 May 16;39(19):5691-701.
11279193	Thoden JB, Wohlers TM, Fridovich-Keil JL, Holden HM: Molecular basis for severe epimerase deficiency galactosemia. X-ray structure of the human V94m-substituted UDP-galactose 4-epimerase. J Biol Chem. 2001 Jun 8;276(23):20617-23. Epub 2001 Mar 7.
8593531	Daude N, Gallaher TK, Zeschnigk M, Starzinski-Powitz A, Petry KG, Haworth IS, Reichardt JK: Molecular cloning, characterization, and mapping of a full-length cDNA encoding human UDP-galactose 4'-epimerase. Biochem Mol Med. 1995 Oct;56(1):1-7.
9326324	Quimby BB, Alano A, Almashanu S, DeSandro AM, Cowan TM, Fridovich-Keil JL: Characterization of two mutations associated with epimerase-deficiency galactosemia, by use of a yeast expression system for human UDP-galactose-4-epimerase. Am J Hum Genet. 1997 Sep;61(3):590-8.
9538513	Maceratesi P, Daude N, Dallapiccola B, Novelli G, Allen R, Okano Y, Reichardt J: Human UDP-galactose 4' epimerase (GALE) gene and identification of five missense mutations in patients with epimerase-deficiency galactosemia. Mol Genet Metab. 1998 Jan;63(1):26-30.
9973283	Wohlers TM, Christacos NC, Harreman MT, Fridovich-Keil JL: Identification and characterization of a mutation, in the human UDP-galactose-4-epimerase gene, associated with generalized epimerase-deficiency galactosemia. Am J Hum Genet. 1999 Feb;64(2):462-70.

# Drug_Target_3_HGNC_ID:
HGNC:4116

# Drug_Target_3_HPRD_ID:
06092

# Drug_Target_3_ID:
2762

# Drug_Target_3_Locus:
1p36-p35

# Drug_Target_3_Molecular_Weight:
38282

# Drug_Target_3_Name:
UDP-glucose 4-epimerase

# Drug_Target_3_Number_of_Residues:
348

# Drug_Target_3_PDB_ID:
1EK6

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_3_Protein_Sequence:
>UDP-glucose 4-epimerase
MAEKVLVTGGAGYIGSHTVLELLEAGYLPVVIDNFHNAFRGGGSLPESLRRVQELTGRSV
EFEEMDILDQGALQRLFKKYSFMAVIHFAGLKAVGESVQKPLDYYRVNLTGTIQLLEIMK
AHGVKNLVFSSSATVYGNPQYLPLDEAHPTGGCTNPYGKSKFFIEEMIRDLCQADKTWNA
VLLRYFNPTGAHASGCIGEDPQGIPNNLMPYVSQVAIGRREALNVFGNDYDTEDGTGVRD
YIHVVDLAKGHIAALRKLKEQCGCRIYNLGTGTGYSVLQMVQAMEKASGKKIPYKVVARR
EGDVAACYANPSLAQEELGWTAALGLDRMCEDLWRWQKQNPSGFGTQA

# Drug_Target_3_Reaction:
UDP-glucose = UDP-galactose

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Catalyzes two distinct but analogous reactions:the epimerization of UDP-glucose to UDP-galactose and the epimerization of UDP-N-acetylglucosamine to UDP-N- acetylgalactosamine

# Drug_Target_3_SwissProt_ID:
Q14376

# Drug_Target_3_SwissProt_Name:
GALE_HUMAN

# Drug_Target_3_Synonyms:
EC 5.1.3.2
Galactowaldenase
UDP-galactose 4-epimerase

# Drug_Target_3_Theoretical_pI:
6.71

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasm

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
M87049

# Drug_Target_4_GenBank_ID_Protein:
148189

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
wecB

# Drug_Target_4_Gene_Sequence:
>1131 bp
GTGAAAGTACTGACTGTATTTGGTACGCGCCCGGAAGCCATCAAGATGGCGCCGTTGGTG
CATGCGTTGGCAAAAGATCCTTTTTTTGAGGCTAAAGTTTGCGTCACTGCGCAGCATCGG
GAGATGCTCGATCAGGTGCTGAAACTCTTTTCCATTGTACCTGACTACGATCTCAACATA
ATGCAGCCAGGACAGGGCCTGACAGAGATAACCTGTCGGATTCTGGAAGGGCTAAAACCT
ATTCTTGCCGAGTTCAAACCAGACGTCGTGCTGGTTCACGGCGATACGACGACGACGCTG
GCAACCAGCCTGGCGGCGTTTTATCAGCGTATTCCTGTTGGTCACGTTGAGGCTGGTCTG
CGCACGGGCGATCTCTATTCGCCGTGGCCGGAAGAGGCTAACCGTACATTGACCGGGCAT
CTGGCGATGTATCACTTCTCTCCAACCGAAACTTCCCGGCAAAACTTGCTGCGTGAAAAC
GTTGCGGATAGCCGAATCTTCATTACCGGTAATACAGTCATTGATGCACTGTTATGGGTG
CGTGACCAGGTGATGAGCAGCGACAAGCTGCGTTCAGAACTGGCGGCAAATTACCCGTTT
ATCGACCCCGATAAAAAGATGATTCTGGTGACCGGTCACAGGCGTGAGAGTTTCGGTCGT
GGCTTTGAAGAAATCTGCCACGCGCTGGCAGACATCGCCACCACGCACCAGGACATCCAG
ATTGTCTATCCGGTGCATCTCAACCCGAACGTCAGAGAACCGGTCAATCGCATTCTGGGG
CATGTGAAAAATGTCATTCTGATCGATCCCCAGGAGTATTTACCGTTTGTCTGGCTGATG
AACCACGCCTGGCTGATTTTGACCGACTCAGGCGGCATTCAGGAAGAAGCGCCTTCGCTG
GGGAAACCTGTGCTGGTGATGCGCGATACCACTGAGCGTCCGGAAGCGGTGACGGCGGGT
ACGGTGCGTCTGGTAGGCACGGATAAGCAGCGAATTGTCGAGGAAGTGACGCGTCTTTTA
AAAGACGAAAACGAATATCAAGCTATGAGCCGCGCCCATAACCCGTATGGTGATGGTCAG
GCATGCTCTCGCATTCTGGAAGCGTTAAAAAATAATCGGATATCACTATGA

# Drug_Target_4_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_4_General_References:
11106477	Campbell RE, Mosimann SC, Tanner ME, Strynadka NC: The structure of UDP-N-acetylglucosamine 2-epimerase reveals homology to phosphoglycosyl transferases. Biochemistry. 2000 Dec 12;39(49):14993-5001.
1379743	Daniels DL, Plunkett G 3rd, Burland V, Blattner FR: Analysis of the Escherichia coli genome: DNA sequence of the region from 84.5 to 86.5 minutes. Science. 1992 Aug 7;257(5071):771-8.
7559340	Marolda CL, Valvano MA: Genetic analysis of the dTDP-rhamnose biosynthesis region of the Escherichia coli VW187 (O7:K1) rfb gene cluster: identification of functional homologs of rfbB and rfbA in the rff cluster and correct location of the rffE gene. J Bacteriol. 1995 Oct;177(19):5539-46.
8170390	Macpherson DF, Manning PA, Morona R: Characterization of the dTDP-rhamnose biosynthetic genes encoded in the rfb locus of Shigella flexneri. Mol Microbiol. 1994 Jan;11(2):281-92.
8226648	Kiino DR, Licudine R, Wilt K, Yang DH, Rothman-Denes LB: A cytoplasmic protein, NfrC, is required for bacteriophage N4 adsorption. J Bacteriol. 1993 Nov;175(21):7074-80.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
2608

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
42245

# Drug_Target_4_Name:
UDP-N-acetylglucosamine 2-epimerase

# Drug_Target_4_Number_of_Residues:
376

# Drug_Target_4_PDB_ID:
1VGV

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF02350	Epimerase_2

# Drug_Target_4_Protein_Sequence:
>UDP-N-acetylglucosamine 2-epimerase
MKVLTVFGTRPEAIKMAPLVHALAKDPFFEAKVCVTAQHREMLDQVLKLFSIVPDYDLNI
MQPGQGLTEITCRILEGLKPILAEFKPDVVLVHGDTTTTLATSLAAFYQRIPVGHVEAGL
RTGDLYSPWPEEANRTLTGHLAMYHFSPTETSRQNLLRENVADSRIFITGNTVIDALLWV
RDQVMSSDKLRSELAANYPFIDPDKKMILVTGHRRESFGRGFEEICHALADIATTHQDIQ
IVYPVHLNPNVREPVNRILGHVKNVILIDPQEYLPFVWLMNHAWLILTDSGGIQEEAPSL
GKPVLVMRDTTERPEAVTAGTVRLVGTDKQRIVEEVTRLLKDENEYQAMSRAHNPYGDGQ
ACSRILEALKNNRISL

# Drug_Target_4_Reaction:
UDP-N-acetyl-D-glucosamine = UDP-N-acetyl-D-mannosamine

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Catalyzes the reversible epimerization at C-2 of UDP-N- acetylglucosamine (UDP-GlcNAc) and thereby provides bacteria with UDP-N-acetylmannosamine (UDP-ManNAc), the activated donor of ManNAc residues. Also involved in bacteriophage N4 adsorption

# Drug_Target_4_SwissProt_ID:
P27828

# Drug_Target_4_SwissProt_Name:
WECB_ECOLI

# Drug_Target_4_Synonyms:
Bacteriophage N4 adsorption protein C
EC 5.1.3.14
UDP-GlcNAc-2- epimerase

# Drug_Target_4_Theoretical_pI:
6.32

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Golgi apparatus
Golgi stack
Golgi stack membrane
single-pass type II membrane protein. Membrane-b

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
ABO

# Drug_Target_5_GenBank_ID_Gene:
J05175

# Drug_Target_5_GenBank_ID_Protein:
340078

# Drug_Target_5_GeneCard_ID:
ABO

# Drug_Target_5_Gene_Name:
ABO

# Drug_Target_5_Gene_Sequence:
>1062 bp
ATGGCCGAGGTGTTGCGGACGCTGGCCGGAAAACCAAAATGCCACGCACTTCGACCTATG
ATCCTTTTCCTAATAATGCTTGTCTTGGTCTTGTTTGGTTACGGGGTCCTAAGCCCCAGA
AGTCTAATGCCAGGAAGCCTGGAACGGGGGTTCTGCATGGCTGTTAGGGAACCTGACCAT
CTGCAGCGCGTCTCGTTGCCAAGGATGGTCTACCCCCAGCCAAAGGTGCTGACACCGTGG
AAGGATGTCCTCGTGGTGACCCCTTGGCTGGCTCCCATTGTCTGGGAGGGCACATTCAAC
ATCGACATCCTCAACGAGCAGTTCAGGCTCCAGAACACCACCATTGGGTTAACTGTGTTT
GCCATCAAGAAATACGTGGCTTTCCTGAAGCTGTTCCTGGAGACGGCGGAGAAGCACTTC
ATGGTGGGCCACCGTGTCCACTACTATGTCTTCACCGACCAGCTGGCCGCGGTGCCCCGC
GTGACGCTGGGGACCGGTCGGCAGCTGTCAGTGCTGGAGGTGCGCGCCTACAAGCGCTGG
CAGGACGTGTCCATGCGCCGCATGGAGATGATCAGTGACTTCTGCGAGCGGCGCTTCCTC
AGCGAGGTGGATTACCTGGTGTGCGTGGACGTGGACATGGAGTTCCGCGACCACGTGGGC
GTGGAGATCCTGACTCCGCTGTTCGGCACCCTGCACCCCGGCTTCTACGGAAGCAGCCGG
GAGGCCTTCACCTACGAGCGCCGGCCCCAGTCCCAGGCCTACATCCCCAAGGACGAGGGC
GATTTCTACTACCTGGGGGGGTTCTTCGGGGGGTCGGTGCAAGAGGTGCAGCGGCTCACC
AGGGCCTGCCACCAGGCCATGATGGTCGACCAGGCCAACGGCATCGAGGCCGTGTGGCAC
GACGAGAGCCACCTGAACAAGTACCTGCTGCGCCACAAACCCACCAAGGTGCTCTCCCCC
GAGTACTTGTGGGACCAGCAGCTGCTGGGCTGGCCCGCCGTCCTGAGGAAGCTGAGGTTC
ACTGCGGTGCCCAAGAACCACCAGGCGGTCCGGAACCCGTGA

# Drug_Target_5_General_Function:
Involved in transferase activity, transferring hexosyl groups

# Drug_Target_5_General_References:
12198488	Patenaude SI, Seto NO, Borisova SN, Szpacenko A, Marcus SL, Palcic MM, Evans SV: The structural basis for specificity in human ABO(H) blood group biosynthesis. Nat Struct Biol. 2002 Sep;9(9):685-90.
2104828	Yamamoto F, Marken J, Tsuji T, White T, Clausen H, Hakomori S: Cloning and characterization of DNA complementary to human UDP-GalNAc: Fuc alpha 1----2Gal alpha 1----3GalNAc transferase (histo-blood group A transferase) mRNA. J Biol Chem. 1990 Jan 15;265(2):1146-51.
2121736	Yamamoto F, Hakomori S: Sugar-nucleotide donor specificity of histo-blood group A and B transferases is based on amino acid substitutions. J Biol Chem. 1990 Nov 5;265(31):19257-62.
2333095	Yamamoto F, Clausen H, White T, Marken J, Hakomori S: Molecular genetic basis of the histo-blood group ABO system. Nature. 1990 May 17;345(6272):229-33.
7598760	Bennett EP, Steffensen R, Clausen H, Weghuis DO, van Kessel AG: Genomic cloning of the human histo-blood group ABO locus. Biochem Biophys Res Commun. 1995 Jan 5;206(1):318-25.
7779106	Bennett EP, Steffensen R, Clausen H, Weghuis DO, Geurts van Kessel A: Genomic cloning of the human histo-blood group ABO locus. Biochem Biophys Res Commun. 1995 Jun 6;211(1):347.
9800297	Olsson ML, Chester MA: Heterogeneity of the blood group Ax allele: genetic recombination of common alleles can result in the Ax phenotype. Transfus Med. 1998 Sep;8(3):231-8.

# Drug_Target_5_HGNC_ID:
HGNC:79

# Drug_Target_5_HPRD_ID:
05821

# Drug_Target_5_ID:
237

# Drug_Target_5_Locus:
9q34.1-q34.2

# Drug_Target_5_Molecular_Weight:
40934

# Drug_Target_5_Name:
Histo-blood group ABO system transferase

# Drug_Target_5_Number_of_Residues:
354

# Drug_Target_5_PDB_ID:
1LZI

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF03414	Glyco_transf_6

# Drug_Target_5_Protein_Sequence:
>Histo-blood group ABO system transferase
MAEVLRTLAGKPKCHALRPMILFLIMLVLVLFGYGVLSPRSLMPGSLERGFCMAVREPDH
LQRVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTV
FAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKR
WQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSS
REAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVW
HDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNP

# Drug_Target_5_Reaction:
UDP-galactose + alpha-L-fucosyl-(1->2)-D-galactosyl-R = UDP + alpha-D-galactosyl-(1->3)-[alpha-L-fucosyl(1->2)]-D-galactosyl-R

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
This protein is the basis of the ABO blood group system. The histo-blood group ABO involves three carbohydrate antigens:A, B, and H. A, B, and AB individuals express a glycosyltransferase activity that converts the H antigen to the A antigen (by addition of UDP-GalNAc) or to the B antigen (by addition of UDP-Gal), whereas O individuals lack such activity

# Drug_Target_5_SwissProt_ID:
P16442

# Drug_Target_5_SwissProt_Name:
BGAT_HUMAN

# Drug_Target_5_Synonyms:
A transferase)
EC 2.4.1.37
EC 2.4.1.40
Fucosylglycoprotein 3-alpha- galactosyltransferase
Fucosylglycoprotein alpha-N-acetylgalactosaminyltransferase
Glycoprotein-fucosylgalactoside alpha- galactosyltransferase
Histo-blood group A transferase
Histo-blood group B transferase
NAGAT

# Drug_Target_5_Theoretical_pI:
9.24

# Drug_Target_5_Transmembrane_Regions:
33-53

# Drug_Target_6_Cellular_Location:
Cell inner membrane
peripheral membrane protein

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
X52644

# Drug_Target_6_GenBank_ID_Protein:
809684

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
murG

# Drug_Target_6_Gene_Sequence:
>1068 bp
ATGAGTGGTCAAGGAAAGCGATTAATGGTGATGGCAGGCGGAACCGGTGGACATGTATTC
CCGGGACTGGCGGTTGCGCACCATCTAATGGCTCAGGGTTGGCAAGTTCGCTGGCTGGGG
ACTGCCGACCGTATGGAAGCGGACTTAGTGCCAAAACATGGCATCGAAATTGATTTCATT
CGTATCTCTGGTCTGCGTGGAAAAGGTATAAAAGCACTGATAGCTGCCCCGCTGCGTATC
TTCAACGCCTGGCGTCAGGCGCGGGCGATTATGAAAGCGTACAAACCTGACGTGGTGCTC
GGTATGGGAGGCTACGTGTCAGGTCCAGGTGGTCTGGCCGCGTGGTCGTTAGGCATTCCG
GTTGTACTTCATGAACAAAACGGTATTGCGGGCTTAACCAATAAATGGCTGGCGAAGATT
GCCACCAAAGTGATGCAGGCGTTTCCAGGTGCTTTCCCTAATGCGGAAGTAGTGGGTAAC
CCGGTGCGTACCGATGTGTTGGCGCTGCCGTTGCCGCAGCAACGTTTGGCTGGACGTGAA
GGTCCGGTTCGTGTGCTGGTAGTGGGTGGTTCTCAGGGCGCACGCATTCTTAACCAGACA
ATGCCGCAGGTTGCTGCGAAACTGGGTGATTCAGTCACTATCTGGCATCAGAGCGGCAAA
GGTTCGCAACAATCCGTTGAACAGGCGTATGCCGAAGCGGGGCAACCGCAGCATAAAGTG
ACGGAATTTATTGATGATATGGCGGCGGCGTATGCGTGGGCGGATGTCGTCGTTTGCCGC
TCCGGTGCGTTAACGGTGAGTGAAATCGCCGCGGCAGGACTACCGGCGTTGTTTGTGCCG
TTTCAACATAAAGACCGCCAGCAATACTGGAATGCGCTACCGCTGGAAAAAGCGGGCGCA
GCCAAAATTATCGAGCAGCCACAGCTTAGCGTGGATGCTGTCGCCAACACCCTGGCCGGG
TGGTCGCGAGAAACCTTATTAACCATGGCAGAACGCGCCCGCGCTGCATCCATTCCGGAT
GCCACCGAGCGAGTGGCAAATGAAGTGAGCCGGGTTGCCCGGGCGTAA

# Drug_Target_6_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_6_General_References:
10892798	Ha S, Walker D, Shi Y, Walker S: The 1.9 A crystal structure of Escherichia coli MurG, a membrane-associated glycosyltransferase involved in peptidoglycan biosynthesis. Protein Sci. 2000 Jun;9(6):1045-52.
1630901	Yura T, Mori H, Nagai H, Nagata T, Ishihama A, Fujita N, Isono K, Mizobuchi K, Nakata A: Systematic sequencing of the Escherichia coli genome: analysis of the 0-2.4 min region. Nucleic Acids Res. 1992 Jul 11;20(13):3305-8.
1649817	Mengin-Lecreulx D, Texier L, Rousseau M, van Heijenoort J: The murG gene of Escherichia coli codes for the UDP-N-acetylglucosamine: N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase involved in the membrane steps of peptidoglycan synthesis. J Bacteriol. 1991 Aug;173(15):4625-36.
2187180	Mengin-Lecreulx D, Texier L, van Heijenoort J: Nucleotide sequence of the cell-envelope murG gene of Escherichia coli. Nucleic Acids Res. 1990 May 11;18(9):2810.
2197603	Ikeda M, Wachi M, Jung HK, Ishino F, Matsuhashi M: Nucleotide sequence involving murG and murC in the mra gene cluster region of Escherichia coli. Nucleic Acids Res. 1990 Jul 11;18(13):4014.
8449890	Bupp K, van Heijenoort J: The final step of peptidoglycan subunit assembly in Escherichia coli occurs in the cytoplasm. J Bacteriol. 1993 Mar;175(6):1841-3.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
2651

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
37815

# Drug_Target_6_Name:
UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase

# Drug_Target_6_Number_of_Residues:
355

# Drug_Target_6_PDB_ID:
1NLM

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
PF03033	Glyco_transf_28
PF04101	Glyco_tran_28_C

# Drug_Target_6_Protein_Sequence:
>UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase
MSGQGKRLMVMAGGTGGHVFPGLAVAHHLMAQGWQVRWLGTADRMEADLVPKHGIEIDFI
RISGLRGKGIKALIAAPLRIFNAWRQARAIMKAYKPDVVLGMGGYVSGPGGLAAWSLGIP
VVLHEQNGIAGLTNKWLAKIATKVMQAFPGAFPNAEVVGNPVRTDVLALPLPQQRLAGRE
GPVRVLVVGGSQGARILNQTMPQVAAKLGDSVTIWHQSGKGSQQSVEQAYAEAGQPQHKV
TEFIDDMAAAYAWADVVVCRSGALTVSEIAAAGLPALFVPFQHKDRQQYWNALPLEKAGA
AKIIEQPQLSVDAVANTLAGWSRETLLTMAERARAASIPDATERVANEVSRVARA

# Drug_Target_6_Reaction:
UDP-N-acetylglucosamine + Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)- diphosphoundecaprenol = UDP + GlcNAc-(1->4)-Mur2Ac(oyl-L-Ala-gamma-D-Glu-L-Lys-D-Ala-D-Ala)- diphosphoundecaprenol

# Drug_Target_6_Signals:
None

# Drug_Target_6_Specific_Function:
Cell wall formation. Catalyzes the transfer of a GlcNAc subunit on undecaprenyl-pyrophosphoryl-MurNAc-pentapeptide (lipid intermediate I) to form undecaprenyl-pyrophosphoryl-MurNAc- (pentapeptide)GlcNAc (lipid intermediate II)

# Drug_Target_6_SwissProt_ID:
P17443

# Drug_Target_6_SwissProt_Name:
MURG_ECOLI

# Drug_Target_6_Synonyms:
EC 2.4.1.227
Undecaprenyl-PP-MurNAc-pentapeptide-UDPGlcNAc GlcNAc transferase
pentapeptide

# Drug_Target_6_Theoretical_pI:
10.32

# Drug_Target_6_Transmembrane_Regions:
None

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
Not Available

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
AF498417

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
Not Available

# Drug_Target_7_Gene_Sequence:
>1026 bp
ATGATGAGTCGTTATGAAGAGCTAAGAAAGGAATTGCCGGCGCAGCCGAAAGTCTGGCTG
ATTACAGGTGTGGCGGGCTTTATTGGCTCTAATCTTCTTGAGACTTTGCTAAAGCTTGAT
CAGAAGGTTGTCGGTCTGGATAATTTTGCTACTGGTCATCAGCGGAACCTGGACGAAGTG
CGGTCCTTGGTTAGCGAGAAGCAATGGTCAAATTTTAAATTTATTCAAGGTGATATTCGC
AATCTGGATGATTGCAATAACGCCTGTGCAGGTGTTGATTACGTTTTACATCAAGCTGCC
TTGGGTTCGGTACCGCGTTCTATTAACGATCCGATCACCTCCAATGCAACGAACATCGAT
GGTTTCTTGAATATGCTGATTGCAGCCAGAGATGCCAAGGTGCAGAGTTTCACTTATGCG
GCAAGTAGCTCTACCTATGGAGATCATCCTGGTTTACCGAAGGTGGAGGATACTATAGGT
AAGCCTCTTTCCCCTTATGCGGTTACCAAATATGTGAATGAGCTTTATGCCGATGTGTTT
TCACGCTGCTACGGCTTTTCGACCATTGGGCTTCGTTATTTCAATGTGTTCGGTCGTCGA
CAGGATCCCAATGGTGCCTATGCGGCAGTCATACCAAAATGGACCTCTTCGATGATCCAG
GGTGATGACGTCTATATTAACGGTGATGGCGAGACCAGTCGGGATTTTTGTTATATTGAA
AACACCGTTCAGGCCAATCTGCTTGCTGCAACCGCGGGGCTTGATGCTCGTAATCAAGTT
TACAATATTGCTGTTGGCGGGCGGACGAGTTTGAATCAGTTGTTCTTTGCGCTTCGCGAC
GGCCTTGCCGAAAACGGTGTGTCCTATCACCGGGAACCTGTTTATCGTGATTTTAGGGAG
GGGGATGTACGTCACTCTCTCGCTGATATCAGCAAGGCTGCCAAACTGCTGGGGTATGCG
CCGAAATATGATGTGTCTGCAGGTGTGGCGTTGGCCATGCCTTGGTACATCATGTTTTTG
AAATGA

# Drug_Target_7_General_Function:
Involved in catalytic activity

# Drug_Target_7_General_References:
12057956	Raymond CK, Sims EH, Kas A, Spencer DH, Kutyavin TV, Ivey RG, Zhou Y, Kaul R, Clendenning JB, Olson MV: Genetic variation at the O-antigen biosynthetic locus in Pseudomonas aeruginosa. J Bacteriol. 2002 Jul;184(13):3614-22.

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
4504

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
37749

# Drug_Target_7_Name:
WbpP

# Drug_Target_7_Number_of_Residues:
341

# Drug_Target_7_PDB_ID:
1SB9

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
PF01370	Epimerase

# Drug_Target_7_Protein_Sequence:
>WbpP
MMSRYEELRKELPAQPKVWLITGVAGFIGSNLLETLLKLDQKVVGLDNFATGHQRNLDEV
RSLVSEKQWSNFKFIQGDIRNLDDCNNACAGVDYVLHQAALGSVPRSINDPITSNATNID
GFLNMLIAARDAKVQSFTYAASSSTYGDHPGLPKVEDTIGKPLSPYAVTKYVNELYADVF
SRCYGFSTIGLRYFNVFGRRQDPNGAYAAVIPKWTSSMIQGDDVYINGDGETSRDFCYIE
NTVQANLLAATAGLDARNQVYNIAVGGRTSLNQLFFALRDGLAENGVSYHREPVYRDFRE
GDVRHSLADISKAAKLLGYAPKYDVSAGVALAMPWYIMFLK

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
None

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Q8KN66

# Drug_Target_7_SwissProt_Name:
Q8KN66_PSEAE

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
6.37

# Drug_Target_7_Transmembrane_Regions:
None

#END_DRUGCARD DB02196
